Published in Drug Week, January 5th, 2007
AZ-002 is being developed for the acute treatment of panic attacks associated with panic disorder and AZ-004 is being developed to treat acute agitation in patients with schizophrenia. Both product candidates are currently in phase IIa clinical trials.
Under the terms of the agreement, Alexza and Symphony Capital, a private equity firm, have established Symphony Allegro, Inc., which will provide funding...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.